94 related articles for article (PubMed ID: 18179663)
1. Introducing evidence-based medicine in reimbursement procedures: does it affect the outcome?
Van Wilder P; Dupont A
Value Health; 2008; 11(4):784-7. PubMed ID: 18179663
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement of medicines in Belgium: role of evidence-based medicine.
Van Wilder PB; Dupont AG
Acta Clin Belg; 2009; 64(2):120-8. PubMed ID: 19432024
[TBL] [Abstract][Full Text] [Related]
3. Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013.
Pauwels K; Huys I; De Nys K; Casteels M; Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):859-68. PubMed ID: 25978862
[TBL] [Abstract][Full Text] [Related]
4. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
5. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
6. Similarities and differences between five European drug reimbursement systems.
Franken M; le Polain M; Cleemput I; Koopmanschap M
Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Wonder M; Dunlop S
Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
[TBL] [Abstract][Full Text] [Related]
9. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
Cleemput I; Franken M; Koopmanschap M; le Polain M
Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
[TBL] [Abstract][Full Text] [Related]
10. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
[TBL] [Abstract][Full Text] [Related]
11. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
Kolasa K; Kalo Z; Zah V; Dolezal T
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
[TBL] [Abstract][Full Text] [Related]
12. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries.
Franken M; Stolk E; Scharringhausen T; de Boer A; Koopmanschap M
Health Policy; 2015 Feb; 119(2):195-202. PubMed ID: 25456017
[TBL] [Abstract][Full Text] [Related]
14. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
15. Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets?
Dylst P; Vulto A; Simoens S
J Aging Soc Policy; 2014; 26(3):266-80. PubMed ID: 24716815
[TBL] [Abstract][Full Text] [Related]
16. Introduction of emerging medical devices on the market: a new procedure in Belgium.
Vinck I; Neyt M; Thiry N; Louagie M; Ramaekers D
Int J Technol Assess Health Care; 2007; 23(4):449-54. PubMed ID: 17937833
[TBL] [Abstract][Full Text] [Related]
17. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
[TBL] [Abstract][Full Text] [Related]
20. Implementation of the biosimilar pathway: economic and policy issues.
Grabowski H; Long G; Mortimer R
Seton Hall Law Rev; 2011; 41(2):511-57. PubMed ID: 21739758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
